{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:54:32Z","timestamp":1790848472915,"version":"4.1.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2015,2,15]],"date-time":"2015-02-15T00:00:00Z","timestamp":1423958400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1007\/s10147-015-0786-7","type":"journal-article","created":{"date-parts":[[2015,2,17]],"date-time":"2015-02-17T04:50:19Z","timestamp":1424148619000},"page":"855-865","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":119,"title":["Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan"],"prefix":"10.1007","volume":"20","author":[{"name":"CINV Study Group of Japan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Tamura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Aiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Saeki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichi","family":"Nakanishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiharu","family":"Kamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Baba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Kitagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiko","family":"Maehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mototsugu","family":"Shimokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Hirata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Kitajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,2,15]]},"reference":[{"key":"786_CR1","doi-asserted-by":"crossref","first-page":"4189","DOI":"10.1200\/JCO.2010.34.4614","volume":"29","author":"E Basch","year":"2011","unstructured":"Basch E, Prestrud AA, Hesketh PJ, American Society of Clinical Oncology et al (2011) Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 29:4189\u20134198","journal-title":"J Clin Oncol"},{"issue":"suppl 5","key":"786_CR2","doi-asserted-by":"crossref","first-page":"v232","DOI":"10.1093\/annonc\/mdq194","volume":"21","author":"F Roila","year":"2010","unstructured":"Roila F, Herrstedt J, Aapro M et al (2010) Warr and on behalf of the ESMO\/MASCC Guidelines Working Group: guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 21(suppl 5):v232\u2013v243","journal-title":"Ann Oncol"},{"key":"786_CR3","unstructured":"NCCN clinical practice guidelines in oncology (2014) Antiemetics. Version 2, NCCN.Org"},{"key":"786_CR4","volume-title":"Guidelines for appropriate use of antiemetic drugs, version 1","author":"Japan Society of Clinical Oncology","year":"2010","unstructured":"Japan Society of Clinical Oncology (2010) Guidelines for appropriate use of antiemetic drugs, version 1. Kanehara, Tokyo"},{"key":"786_CR5","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/BF02895775","volume":"22","author":"JA Roscoe","year":"2000","unstructured":"Roscoe JA, Hickok JT, Morrow GR (2000) Patient expectations as predictor of chemotherapy-induced nausea. Ann Behav Med 22:121\u2013126","journal-title":"Ann Behav Med"},{"key":"786_CR6","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1002\/cncr.20718","volume":"101","author":"JA Roscoe","year":"2004","unstructured":"Roscoe JA, Bushunow P, Morrow GR et al (2004) Patient expectation is a strong predictor of severe nausea after chemotherapy: a University of Rochester Community Clinical Oncology Program study of patients with breast carcinoma. Cancer (Phila) 101:2701\u20132708","journal-title":"Cancer (Phila)"},{"key":"786_CR7","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s00520-009-0723-2","volume":"18","author":"JA Roscoe","year":"2010","unstructured":"Roscoe JA, Morrow GR, Colagiuri B et al (2010) Insight in the prediction of chemotherapy-induced nausea. Support Care Cancer 18:869\u2013876","journal-title":"Support Care Cancer"},{"key":"786_CR8","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1345\/aph.1L437","volume":"43","author":"V Shih","year":"2009","unstructured":"Shih V, Wan HS, Chan A (2009) Clinical predictors of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adjuvant doxorubicin and cyclophosphamide. Ann Pharmacother 43:444\u2013452","journal-title":"Ann Pharmacother"},{"key":"786_CR9","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1007\/s00520-009-0737-9","volume":"18","author":"PJ Hesketh","year":"2010","unstructured":"Hesketh PJ, Aapro M, Street JC et al (2010) Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy. Support Care Cancer 18:1171\u20131177","journal-title":"Support Care Cancer"},{"key":"786_CR10","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s00520-010-0899-5","volume":"19","author":"DG Warr","year":"2011","unstructured":"Warr DG, Street JC, Carides AD (2011) Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin-cyclophosphamide-based chemotherapy. Support Care Cancer 19:807\u2013813","journal-title":"Support Care Cancer"},{"key":"786_CR11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00066-010-2196-0","volume":"187","author":"I Fraunholz","year":"2011","unstructured":"Fraunholz I, Grau K, Weiss C et al (2011) Patient- and treatment-related risk factors for nausea and emesis during concurrent chemoradiotherapy. Strahlenther Onkol 187:1\u20136","journal-title":"Strahlenther Onkol"},{"key":"786_CR12","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1007\/s00520-010-0982-y","volume":"19","author":"C Pirri","year":"2011","unstructured":"Pirri C, Katris P, Trotter J et al (2011) Risk factors at pretreatment predicting treatment-induced nausea and vomiting in Australian cancer patients: a prospective, longitudinal, observational study. Support Care Cancer 19:1549\u20131563","journal-title":"Support Care Cancer"},{"key":"786_CR13","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ejphar.2013.10.015","volume":"722","author":"D Warr","year":"2014","unstructured":"Warr D (2014) Prognostic factors for chemotherapy induced nausea and vomiting. Eur J Pharmacol 722:192\u2013196","journal-title":"Eur J Pharmacol"},{"key":"786_CR14","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1002\/cncr.20230","volume":"100","author":"SM Grunberg","year":"2004","unstructured":"Grunberg SM, Deuson RR, Mavros P et al (2004) Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer (Phila) 100:2261\u20132268","journal-title":"Cancer (Phila)"},{"key":"786_CR15","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1007\/s00520-010-1042-3","volume":"19","author":"M Majem","year":"2011","unstructured":"Majem M, Moreno ME, Calvo N et al (2011) Perception of healthcare providers versus patient reported incidence of chemotherapy-induced nausea and vomiting after the addition of NK-1 receptor antagonists. Support Care Cancer 19:1983\u20131990","journal-title":"Support Care Cancer"},{"key":"786_CR16","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1093\/annonc\/mds021","volume":"23","author":"M Aapro","year":"2012","unstructured":"Aapro M, Molassiotis A, Dicato M et al (2012) The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER). Ann Oncol 23:1986\u20131992","journal-title":"Ann Oncol"},{"key":"786_CR17","volume-title":"Emesis patterns of chemotherapy and antiemetic treatments in Western Europe","author":"C Ricarte","year":"2013","unstructured":"Ricarte C, Anger C (2013) Emesis patterns of chemotherapy and antiemetic treatments in Western Europe. European Cancer Congress, Amsterdam"},{"key":"786_CR18","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1200\/JOP.2012.000816","volume":"10","author":"JW Gilmore","year":"2014","unstructured":"Gilmore JW, Peacock NW, Gu A, Szabo S (2014) Antiemetic guideline consistency and incidence of chemotherapy-induced nausea and vomiting in US community oncology practice: INSPIRE study. J Oncol Pract 10:68\u201374","journal-title":"J Oncol Pract"},{"key":"786_CR19","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.suponc.2011.05.002","volume":"9","author":"RM Navari","year":"2011","unstructured":"Navari RM, Gray SE, Kerr AC (2011) Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol 9:188\u2013195","journal-title":"J Support Oncol"},{"key":"786_CR20","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1007\/s00520-005-0803-x","volume":"13","author":"N Neymark","year":"2005","unstructured":"Neymark N, Crott R (2005) Impact of emesis on clinical and economic outcomes of cancer therapy with highly emetogenic chemotherapy regimens: a retrospective analysis of three clinical trials. Support Care Cancer 13:812\u2013818","journal-title":"Support Care Cancer"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-015-0786-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10147-015-0786-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-015-0786-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T06:37:37Z","timestamp":1559111857000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10147-015-0786-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,15]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["786"],"URL":"https:\/\/doi.org\/10.1007\/s10147-015-0786-7","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,15]]}}}